JP2014500862A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500862A5
JP2014500862A5 JP2013536823A JP2013536823A JP2014500862A5 JP 2014500862 A5 JP2014500862 A5 JP 2014500862A5 JP 2013536823 A JP2013536823 A JP 2013536823A JP 2013536823 A JP2013536823 A JP 2013536823A JP 2014500862 A5 JP2014500862 A5 JP 2014500862A5
Authority
JP
Japan
Prior art keywords
cancer
secad
therapeutic agent
cancer therapeutic
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013536823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500862A (ja
JP6243737B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/058076 external-priority patent/WO2012058418A2/en
Publication of JP2014500862A publication Critical patent/JP2014500862A/ja
Publication of JP2014500862A5 publication Critical patent/JP2014500862A5/ja
Application granted granted Critical
Publication of JP6243737B2 publication Critical patent/JP6243737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013536823A 2010-10-27 2011-10-27 E−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法 Active JP6243737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40736710P 2010-10-27 2010-10-27
US61/407,367 2010-10-27
PCT/US2011/058076 WO2012058418A2 (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Publications (3)

Publication Number Publication Date
JP2014500862A JP2014500862A (ja) 2014-01-16
JP2014500862A5 true JP2014500862A5 (enExample) 2014-12-18
JP6243737B2 JP6243737B2 (ja) 2017-12-06

Family

ID=45994754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013536823A Active JP6243737B2 (ja) 2010-10-27 2011-10-27 E−カドヘリンの可溶性細胞外ドメインを標的とする組成物および癌治療のための関連方法

Country Status (13)

Country Link
US (4) US20130287784A1 (enExample)
EP (1) EP2632489B1 (enExample)
JP (1) JP6243737B2 (enExample)
KR (1) KR20140075639A (enExample)
CN (1) CN103582494A (enExample)
AU (1) AU2011319777B2 (enExample)
BR (1) BR112013010535A2 (enExample)
CA (1) CA2816358A1 (enExample)
ES (1) ES2784385T3 (enExample)
MX (2) MX357167B (enExample)
RU (1) RU2013123792A (enExample)
SG (3) SG10202100921YA (enExample)
WO (1) WO2012058418A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
KR20140138956A (ko) * 2012-03-15 2014-12-04 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 E-카드헤린의 세포외 도메인의 저해제를 포함하는 병용 치료법
US9411750B2 (en) * 2012-07-30 2016-08-09 International Business Machines Corporation Efficient calibration of a low power parallel data communications channel
US9474034B1 (en) 2015-11-30 2016-10-18 International Business Machines Corporation Power reduction in a parallel data communications interface using clock resynchronization
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service
KR102149822B1 (ko) 2016-03-10 2020-08-31 케이블텔레비젼래버러토리즈,인코포레이티드 레이턴시 감소를 위한 시스템들 및 방법들
US10321351B2 (en) 2017-03-02 2019-06-11 Cable Television Laboratories, Inc. System and method for grant assignment
US10738127B2 (en) 2016-06-10 2020-08-11 Veritas Biotecnologia Ltda Monoclonal antibodies prevent cell surface protein shedding and block tumor growth
US10420085B2 (en) 2016-10-07 2019-09-17 Cable Television Laboratories, Inc. System and method for grant assignment
US12225536B2 (en) 2016-10-07 2025-02-11 Cable Television Laboratories, Inc. System and method for grant assignment
EP3791570A4 (en) 2018-05-11 2022-01-26 Axon Enterprise, Inc. SYSTEMS AND METHODS OF CROSS-EDITING
CN115066439A (zh) * 2020-01-10 2022-09-16 科凌生物医疗有限公司 上皮钙黏素特异性抗体

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR940009084B1 (ko) 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
AU5669494A (en) * 1992-11-17 1994-06-08 Yale University Human homolog of the e-cadherin gene and methods based thereon
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6723320B2 (en) * 1996-07-24 2004-04-20 Gsf Forschungszentrum Fur Umwelt Und Geshundheit Gmbh Mutations of E cadherin as a basis for the diagnosis and therapy of human malignant tumors
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
WO2002034880A2 (en) * 2000-10-23 2002-05-02 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
AU2002258621A1 (en) 2001-03-28 2002-10-21 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
CA2513559A1 (en) 2003-01-23 2004-08-05 University Of Rochester Herpesvirus amplicon particles
JP5723270B2 (ja) * 2009-05-01 2015-05-27 国立大学法人 東京大学 抗カドヘリン抗体

Similar Documents

Publication Publication Date Title
JP2014500862A5 (enExample)
JP2020536109A5 (enExample)
BR112019025188A2 (pt) Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
KR20220158053A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체
RU2013123792A (ru) Композиции, нацеленные на растворимый внеклеточный домен е-кадгерина, и связанные с ними способы лечения онкологических заболеваний
US12371507B2 (en) CDCP1 antibodies and antibody drug conjugates
JP2016509582A5 (enExample)
EP3378873B1 (en) Anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma
JP2012100677A5 (enExample)
JP7374765B2 (ja) 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用
CN114207117A (zh) 用于调节巨噬细胞活性的方法
JP2016520527A (ja) 細胞表面grp78に結合する抗体を使用したがんの処置
TWI402076B (zh) 抗介白素-20抗體用於製造治療中風的醫藥組合物之用途
JP2015514062A5 (enExample)
WO2018124009A1 (ja) 低体温改善剤
CN114929275A (zh) 使用dkk-1抑制剂治疗癌症的方法
US9914768B2 (en) Anti-S100A7 antibodies for the treatment and diagnosis of cancer
KR102769405B1 (ko) Igfbp-3 및 그것의 수용체와 관련되는 질환의 치료
CN103421112B (zh) 一种抗肠道病毒的结合分子及其用途
AU2018285523A1 (en) Antibody drug conjugates that bind LGR5
EP3277306B1 (en) Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for use in a treatment of liver disorders
Zhang et al. Prophylactic efficacy of an intranasal spray with 2 synergetic antibodies neutralizing Omicron
JP2019505516A (ja) インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法
US20240174741A1 (en) Il-38-specific antibodies
HK40118760A (zh) 特异性结合api5蛋白的抗体